A kind of new synthetic method of entecavir compound

A technology of entecavir and synthetic method, which is applied in the field of new synthesis of entecavir compounds, can solve the problems of high technical requirements of the method, rare raw materials, and expensive process routes

Active Publication Date: 2016-08-24
SHANDONG LUOXIN PHARMA GRP CO LTD +1
View PDF12 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0019] The purpose of the present invention is to provide a synthetic method of an entecavir compound and its intermediates, to solve the problems in the prior art that the cost of the process route is high, the raw materials are rare, and the technical requirements of the method are high.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of new synthetic method of entecavir compound
  • A kind of new synthetic method of entecavir compound
  • A kind of new synthetic method of entecavir compound

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0101] 1) Synthesis of compound 2

[0102]

[0103] Dimethyl (S)-3-hydroxyadipate (190.2g, 1mol) was dissolved in 2000ml of dichloromethane, and imidazole (81.7g, 1.2mol) and TBSCl (165.8g, 1.1mol) were added sequentially. Stir at room temperature for 4 hours. The reaction was quenched by adding 1500 ml of water, and the liquid was separated. The organic phase was washed twice with 2000 ml of water, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain compound 2 (289.25 g, yield 95%).

[0104] 2) Synthesis of compound 2

[0105]

[0106] Dimethyl (S)-3-hydroxyadipate (190.2g, 1mol) was dissolved in 2000ml tetrahydrofuran, and pyridine (103.1g, 1.3mol) and TBSCl (180.9g, 1.2mol) were added in sequence. The reaction solution was kept at room temperature. Stir for 3 hours. The reaction was quenched by adding 1500 ml of water, and the liquid was separated. The organic phase was washed twice with 2000 ml of water, dried over anhydrous sodium ...

Embodiment 2

[0108] 1) Synthesis of compound 3

[0109]

[0110] Compound 2 (228.35 g, 750 mmol) was dissolved in 12,500 ml of methanol, 25% sodium methoxide methanol solution (486 g, 2250 mmol) was added, and the mixture was heated to reflux for 3 hours. After the reaction, it was concentrated under reduced pressure to remove methanol. The residue was added with 5000ml 0.5M hydrochloric acid solution, extracted with 2500ml dichloromethane, the organic phase was washed twice with 2500ml water, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and crude product column chromatography (petroleum ether / ethyl acetate=80: 1) Compound 3 (147.1 g, yield 72%) was purified.

[0111] 2) Synthesis of compound 3

[0112]

[0113] Compound 2 (243.6 g, 0.8 mol) was dissolved in 12,500 ml of tert-butanol, and 25% potassium tert-butoxide (t-BuOK) solution (179.5 g, 1.6 mol) in tert-butanol was added, and heated to reflux for 2 hours. After the reaction, tert-butanol was concen...

Embodiment 3

[0115] 1) Synthesis of compound 4

[0116]

[0117] Compound 3 (136.2g, 500mmol) was dissolved in 280ml of toluene, added ethylene glycol (93.1g, 1500mmol) and p-toluenesulfonic acid monohydrate (7.6g, 40mmol), heated to reflux and separated water, and reacted for 8 hours. When there is no moisture, stop heating and cool to room temperature. Add 750 ml of saturated sodium bicarbonate solution and stir for 10 minutes, separate the organic phase, wash twice with 1000 ml of water, dry with anhydrous sodium sulfate, filter, and concentrate under reduced pressure to obtain compound 4 (145.6 g, yield 92%).

[0118] 2) Synthesis of compound 4

[0119]

[0120] Dissolve compound 3 (136.2g, 500mmol) in 280ml of dichloromethane, add ethylene glycol (62.1g, 1000mmol) and pyridine hydrochloride (5.8g, 50mmol), heat to reflux and separate water, and react for 9 hours. After moisture is generated, stop heating and cool to room temperature. Add 750 ml of saturated sodium bicarbonate solution and...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the field of drug synthesis and relates to an entecavir compound and a synthetic method of an intermediate of the entecavir compound. The novel synthetic method comprises: by taking (S)-3-hydroxyl dimethyl adipate as an initial raw material, preparing an intermediate 9 through hydroxyl TBS protection, Dieckmann condensation reaction, ketone protection to ketal, ester group reduction to hydroxyl, hydroxyl protection, deprotection, ketone to silyl enol ether and Rubottom oxidizing reaction; and preparing entecavir from the intermediate 9 through wittig reaction, Mitsunobu reaction, silicon preventing radical group removal and basic hydrolysis. The novel synthetic method provided by the invention is mild and easily controllable in reaction condition, simple to operate, high in product yield, high in purity and suitable for industrialized mass production.

Description

Technical field [0001] The invention belongs to the field of drug synthesis, and relates to a new synthesis method of entecavir compound. Background technique [0002] Entecavir, chemical name: [1-S-(1α, 3α, 4β)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2 -Methylenecyclopentyl]-6H-purin-6-one, is an effective and selective deoxyguanine nucleoside analog that inhibits hepatitis B virus replication, and has an inhibitory effect on hepatitis B virus (HBV) polymerase , Was researched and developed by Bristol-MyersSquibb (Bristol-Myers Squibb), and was listed in the US in April 2005. Its structure is as follows: [0003] [0004] In vitro tests have shown that Entecavir is more effective than other nucleoside analogs. Animal models and human clinical research results show that Entecavir has a strong inhibitory effect on hepatitis B virus replication and reduces serum viral DNA levels. It is still effective against lamivudine-resistant mutant virus strains, and no obvious adv...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C07D473/18C07F7/18
CPCC07D473/18C07F7/1804
Inventor 侯俊凯王文鑫司马芹
Owner SHANDONG LUOXIN PHARMA GRP CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap